Biological
Human Papillomavirus Vaccine V503 clinical trials
- studies test it
- 10
- open now
- 1
- in phase 3
- 10
- first study started
- 2009
Keep track of what changes. Save the Human Papillomavirus Vaccine V503 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
- V503
- 10
Studies by the year they started
10 studies that test it; most in 2011 (2)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 2 |
| 2014 | 1 |
| 2017 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 3
- 10
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 0
Studies
Open first, then newest update. How each study uses Human Papillomavirus Vaccine V503 is read from its arms, and is right about nine times in ten.
Testing it · 10
- A Clinical Study of V503 in Chinese Females Who Have Previously Received a Bivalent Human Papillomavirus (HPV) Vaccine (V503-108)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07785843Written as V503
- Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023)Active, not recruitingPhase 3Merck Sharp & Dohme LLCNCT03998254Written as V503
- Efficacy, Immunogenicity, and Safety Study of V503 (9-valent Human Papillomavirus [9vHPV] Vaccine) in Japanese Males (V503-064)CompletedPhase 3Merck Sharp & Dohme LLCNCT04635423Written as V503
- Immunobridging Study of 9- Valent Human Papillomavirus (9vHPV) Vaccine (V503) in Chinese Females 9 to 45 Years of Age (V503-024)CompletedPhase 3Merck Sharp & Dohme LLCNCT03903562Written as V503
- A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002)CompletedPhase 3Merck Sharp & Dohme LLCNCT00943722Written as V503
- Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)CompletedPhase 3Merck Sharp & Dohme LLCNCT03158220Written as V503
- Immunogenicity and Tolerability of V503 Versus GARDASIL (V503-009)CompletedPhase 3Merck Sharp & Dohme LLCNCT01304498Written as V503
- A Study of the Safety, Tolerability, and Immunogenicity of a 9-valent Human Papillomavirus Vaccine ([9vHPV]; V503) Administered to 9- to 15-Year-Old Japanese Girls (V503-008).CompletedPhase 3Merck Sharp & Dohme LLCNCT01254643Written as V503
- A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)CompletedPhase 3Merck Sharp & Dohme LLCNCT01047345Written as V503
- A Study to Compare Immune Response of V503 to Gardasil in 16- to 26-year-old Men (V503-020)CompletedPhase 3Merck Sharp & Dohme LLCNCT02114385Written as V503
Given in every arm · 2 — Human Papillomavirus Vaccine V503 is usual care beside what is tested
- A Study of V503 Given Concomitantly With Menactra™ and Adacel™ in 11 to 15 Year Olds (V503-005)CompletedPhase 3Merck Sharp & Dohme LLCNCT00988884Written as V503
- Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)CompletedPhase 3Merck Sharp & Dohme LLCNCT00543543Written as Experimental: V503